Frequency of cardiovascular events during Ponatinib therapy: A single centre experience

Abstract

The current treatment of BCR-ABL positive chronic myeloid leukemia (CML) in chronic phase is primarily based on targeted therapies involving tyrosine kinase inhibitors (TKIs). Tyrosine kinase inhibitors, such as the first generation drug imatinib, directly affect the oncogenic origin of the disease by inhibiting the BCR-ABL kinase activity.